Novo Presents Cagrisema Data Ahead of FDA Decision
Published 2 d ago2 sourcesEvidence: Reported
Eisai presented five-year data from the Clarity AD study and extension, indicating that continuous Leqembi treatment yields increased clinical benefit in early Alzheimer's patients. The data strengthens the drug's long-term efficacy profile, though safety and real-world durability remain to be fully assessed. This is a positive development for Bioarctic and its partner, potentially influencing Alzheimer's treatment standards.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Unknown
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported